GlassScriptPhysician profile
Nancy Y Luo
NPI 1417186438
$117,587.91
in general payments reported to CMS, 2019-2025
21 companies · $50K in 2025
The $50K reported for 2025 was more than what 92% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,999 · 2020: $11K · 2021: $1,891 · 2022: $6,468 · 2023: $32K · 2024: $12K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $16K · Travel and Lodging: $8,115 · Food and Beverage: $3,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,601.52 |
| Consulting Fee | $15,578.00 |
| Travel and Lodging | $8,114.86 |
| Food and Beverage | $3,896.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $41,518.51 | 2021-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $40,064.44 | 2019-2025 | Farxiga, Wainua |
| Scpharmaceuticals INC. | $22,746.03 | 2023-2024 | |
| Pfizer INC. | $8,621.39 | 2020-2025 | |
| Abiomed | $1,684.33 | 2020-2025 | Impella |
| Abbott Laboratories | $1,361.74 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Bayer Healthcare Pharmaceuticals INC. | $604.95 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $229.19 | 2019-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.15 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $116.97 | 2019 | |
| Medtronic Vascular, INC. | $110.28 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.65 | 2022 | |
| Heartflow, INC. | $35.42 | 2020 | |
| Merck Sharp & Dohme LLC | $34.17 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.73 | 2022 | |
| Vifor Pharma, INC. | $27.49 | 2022 | |
| Edwards Lifesciences Corporation | $25.92 | 2024 | Sapien 3 Ultra Resilia |
| Itamar Medical INC | $23.40 | 2022 | |
| Biotronik INC. | $20.16 | 2019 | |
| Medtronic, INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.